Oxford BioTherapeutics Takes Exclusive Rights to Use Xenomouse® Antibodies and ADC Technology

News   May 16, 2014

 
Oxford BioTherapeutics Takes Exclusive Rights to Use Xenomouse® Antibodies and ADC Technology
 
 
 

RELATED ARTICLES

“Lymphoma Micro-reactor” Targets Chemo-Resistant Lymphoma

News

Researchers have developed a “lymphoma micro-reactor” device that exposes human lymphomas to fluid flow similar to that in the lymphatics and parts of the lymph node.

READ MORE

Fat Cells Seem to Remember Unhealthy Diet

News

Fat cells can be damaged in a short amount of time when they are exposed to the fatty acid palmitate or the hormone TNF-alpha through a fatty diet, a new study shows. The researchers hope this new knowledge may be used to develop new preventive strategies for diabetes.

READ MORE

Targeting Telomerase: A Therapeutic Strategy for Difficult-to-Treat Melanoma

News

Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in Oncogene.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE